Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
By Nikita Chaurasia  Date: 2020-05-18

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial for assessing a possible coronavirus vaccine.

The Prime Minister of Canada, Justin Trudeau made this announcement on Saturday during his daily address to the nation.

Trudeau stated that research and development require time, and should be done right. However, despite the fact, this is a good news. The National Research Council would be working closely alongside the manufacturers, so in case the clinical trials are a success, the coronavirus vaccine can be manufactured and distributed at scale.

The clinical trials have been authorized by Health Canada and would be carried out at the CCfV (Canadian Centre for Vaccinology) at the Dalhousie University, Halifax. The CCfV team comprises 45 people working together on a potential vaccine candidate from CanSino Biologics.

Health Canada, while speaking about the trial, stated that the approval for going ahead with the trial was done after a careful review of the submitted trial application, which fulfilled the necessary quality and safety requirements.

Researchers stated that approximately 600 participants would be required to commence the clinical study.

Scott Halperin, CCfV Director and professor of immunology, pediatrics, and microbiology at Dalhousie University, stated that they would be further building upon the trials that have already started in China.   

Halperin further added that a vaccine strain known as Ad5-nCoV utilizes another virus which is modified to not cause infection within humans. It expresses a COVID-19 antigen called spike protein on its surface. If the trial participants create antibodies to tackle this antigen, then the formulation might prove helpful against the coronavirus.

Halperin hopes that the clinical trials would start in the coming two weeks once the team receives its approval from the ethics board.

Less than 100 participants of different ages would be tested in Phase 1. Phase 2 is expected to have more than 500 participants ranging between 18 to 85 years of age.

 

Source credit: https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
By Nikita Chaurasia

San Francisco based digital currency exchange major Coinbase has reportedly announced its acquisition of the crypto prime brokerage platform, Tagomi. For eight years, Coinbase has been known for its credibility in the field of industry-leading tradin...

National Congress of China recommends government-led blockchain fund
National Congress of China recommends government-led blockchain fund
By Nikita Chaurasia

The parliament of China, National People’s Congress, has reportedly given a suggestion for a blockchain development fund, backed by the government to be able to build up a good governance system. The most powerful and important political adviso...

Researchers to investigate the risk of airborne viruses in buildings
Researchers to investigate the risk of airborne viruses in buildings
By Nikita Chaurasia

As the world gradually paces back to normalcy after recuperating from the devastating effects of COVID-19, a research team from DOE’s Lawrence Berkeley National Laboratory (Berkeley Lab) embarked on the quest to study the risk of airborne virus...

NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
By Nikita Chaurasia

NZME, a News Zealand media giant, has recently unveiled a symbolic US$0.61 (NZ$1) takeover bid for rival Stuff Limited in an attempt for consolidation of the news industry in the country, amid the downturn caused by the coronavirus pandemic. Nine Ent...

Tech Mahindra to benefit from AT&T as it moves ahead with its 5G plan
Tech Mahindra to benefit from AT&T as it moves ahead with its 5G plan
By Nikita Chaurasia

In the midst of the global economic crisis caused by COVID-19, some businesses are still focused on meeting their ongoing contracts. Reportedly, leading telecom carrier, AT&T intends to commence its IT modernization contracts to avoid unnecessary...